Resistance Profile of Osimertinib in Pre-treated Patients With EGFR T790M-Mutated Non-small Cell Lung Cancer

Background: Osimertinib efficacy in pre-treated patients with epidermal growth factor receptor (EGFR) T790M-mutated non-small cell lung cancer (NSCLC) has been demonstrated in clinical trials, but real-world data, particularly regarding resistance profile, remains limited. This study aims to analyze...

Descripción completa

Detalles Bibliográficos
Autores principales: Fernandes, Maria Gabriela O., Sousa, Catarina, Jacob, Maria, Almeida, Leonor, Santos, Vanessa, Araújo, David, Novais Bastos, Hélder, Magalhães, Adriana, Cirnes, Luís, Moura, Conceição Souto, Queiroga, Henrique, Cruz-Martins, Natália, Hespanhol, Venceslau
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8136429/
https://www.ncbi.nlm.nih.gov/pubmed/34026599
http://dx.doi.org/10.3389/fonc.2021.602924

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8136429/
https://www.ncbi.nlm.nih.gov/pubmed/34026599
http://dx.doi.org/10.3389/fonc.2021.602924

Ejemplares similares